While we are on the subject of Personalized Therapy.. Melanoma

Myriad Genetics Launches Sixth Personalized Medicine Product, Prezeon -- to Reveal PTEN Status
December 22, 2008: 06:30 AM ET

Myriad Genetics, Inc. (NASDAQ: MYGN) (www.myriad.com) announced today that it is launching its sixth molecular diagnostic product, Prezeon(TM). The product will be marketed to researchers and physicians to assist them in understanding the status of the PTEN gene, which plays a major role in critical cell-signaling pathways. These pathways have been implicated in cancer progression and provide important information that may guide therapeutic decisions. The price per Prezeon test is $500.


PTEN Gene Associated With Cancer Prognosis and Choice of Chemotherapy




Do I here A UUUUUUUUUUUUUUUU?

What does it spell, HUURRY!!!!!!!!!!!!!!!!!!


jimmy B.